Denali Therapeutics Inc.
COMPOUNDS, COMPOSITIONS AND METHODS
Last updated:
Abstract:
The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, and methods of making and using thereof.
Status:
Application
Type:
Utility
Filling date:
12 Feb 2020
Issue date:
9 Jun 2022